RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy

Summary

This is a pilot study of a fixed dose of Pembrolizumab in combination with two different regimens of hypofractionated radiation. It is designed to demonstrate the activity and safety of the combination treatment in advanced urothelial cancer patients with prior exposure to PD-1 inhibitors.

Timeline

Start

2016-08

Primary completion

2017-08

Completion

2018-12

Outcome

Outcome not reported

Stopped (Enrollment): “Insufficient accrual”

Drugs

Indications